论文部分内容阅读
目的观察伊立替康联合顺铂的化疗方案对复发性卵巢癌的近期疗效及不良反应。方法28例复发性卵巢癌采用顺铂60mg/m2,第1天静脉给药,伊立替康60mg/m2于第1、8d静脉给药,21d为1周期。每例化疗均持续2到4周期以上,每化疗2个周期后评价疗效。结果28例化疗患者中CR7.14%(2/28),PR46.43%(13/28)。毒副反应:以血液系统毒性反应为主,白细胞减少为主,Ⅲ至Ⅳ度白细胞减少为17.86%,血小板减少和血红蛋白减少较轻,无Ⅲ至Ⅳ度血小板减少,腹泻有19例,多数为轻度腹泻,Ⅲ度为7.14%。结论以伊立替康加顺铂的联合化疗治疗复发性卵巢癌具有较好的疗效,毒性反应轻,耐受性较好。
Objective To observe the short-term curative effect and adverse reactions of irinotecan combined with cisplatin chemotherapy on recurrent ovarian cancer. Methods 28 cases of recurrent ovarian cancer with cisplatin 60mg / m2, the first day of intravenous administration of irinotecan 60mg / m2 intravenously on the first and eighth days, 21d for a cycle. Each chemotherapy continued for more than two to four cycles, two cycles after each chemotherapy to evaluate the efficacy. Results Among the 28 chemotherapy patients, CR was 7.14% (2/28) and PR was 46.43% (13/28). Toxic and side effects: the main toxicity of the blood system, the main leukopenia, leukopenia Ⅲ to Ⅳ degree was 17.86%, thrombocytopenia and hemoglobin decreased less, no Ⅲ to Ⅳ thrombocytopenia, diarrhea in 19 cases, the majority of Mild diarrhea, Ⅲ degree was 7.14%. Conclusion The combination of irinotecan plus cisplatin in the treatment of recurrent ovarian cancer has better curative effect, less toxic reaction and better tolerability.